Sep 11 |
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
|
Jul 29 |
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
|
Jun 3 |
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
|
May 24 |
Eledon Pharmaceuticals files to sell 21.1M shares for holders
|
May 9 |
Eledon Pharmaceuticals GAAP EPS of -$0.34 beats by $0.04
|
May 9 |
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
|
May 9 |
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
|
May 7 |
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
|
May 7 |
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
|